Veloce Energy participated in the 5th Annual Sustainability Private Capital Event on December 7-8, 2022 presented jointly by Sustain SoCal and Roth Capital Partners. Venture capitalists and investors from private equity, family offices, endowments, foundations and angels attended the event. Due to factors like high utility connection costs, high utility demand charges, and costly antiquated construction methods, EV charging stations are often un-profitable and take far too long to be deployed. Veloce Energy’s FastGrid software and hardware platform helps eliminate these barriers through its:

• Modular and scalable approach
• Integrated architecture
• Installation techniques
• Integrated resilience

By incorporating the above dynamics, Veloce Energy is focused on mitigating the impact of climate change by reducing carbon emissions, eliminating costs, integrating systems and increasing the profitability of EV charging stations. At the 5th Annual Sustainability Private Capital Event, Veloce Capital presented its novel and innovative ideas for the EV Charging Industry to inform, discuss, and facilitate businesses with industry experts and potential investors. The team at Veloce Energy is positively and dramatically impacting climate change by accelerating the electrification of transportation through technological and business model innovation in EV charging. This two-day virtual event offered a mammoth networking and business opportunity to connect C-level executives with established private sustainability companies, mostly series A/B, in the solar, storage, e-mobility, Smart City, circular economy and water verticals. To learn more about the conference, please visit https://ibn.fm/0AUAF & https://ibn.fm/YBuOk. To learn more about Veloce Energy, please visit (www.veloceenergy.com).

• Industries and governments worldwide have been battered in recent years by the fallout from the COVID pandemic and the war in Ukraine as it pertains to energy access and climate change
• Global industries are pursuing distributed energy resource (“DER”) micro-networks for providing a more localized power infrastructure reliant on carbon-free renewable energy
• North America-based Correlate Infrastructure Partners Inc. is a clean energy solutions innovator that works with clients on reducing their carbon footprint through smart energy utilization decisions and project financing
• Experienced leadership, such as the fiscal management provided by CFO Channing Chen, who was recently featured in a company spotlight, has helped CIPI to augment its financial successes, including record revenues reported during the most recent quarter and one of the largest behind-the-meter solar installations in the United States for global stored energy solutions leader EnerSys

A wide variety of industries have suffered economically through the global COVID pandemic’s impacts on workforces and then the global supply chain difficulties made manifest as a result of Russia’s war with Ukraine. At the same time, severe weather and the further anticipated effects of climate change have raised alarm about impacts on the conditions of livability for humanity globally during the coming decades. “For energy access and climate change, 2022 has been a year of reckoning. These interlocking crises are impacting billions of people and the need to act is clear,” Intel Chief Commercial Officer Christoph Schell wrote in a recent column for the World Economic Forum. “The energy grid is where these crises meet, and the creation of a smart grid is vital in delivering energy resources in the face of supply disruptions while optimizing usage for a healthier planet” (https://ibn.fm/wq3bc). Impetus to develop a smart grid involves efforts to help energy access evolve from single primary source utilities distribution to highly distributed networks of clean renewable energy deployed at the edge of the existing grid in which “energy flows omnidirectionally both to and from the source of generation … and the entire system is balanced for intermittent energy sources like solar and wind in real-time.” Such distributed energy resources (“DER”) would favor more localized microgrids of energy sources rather than large regional distributors (https://ibn.fm/WWiqc). The U.S. Department of Energy (“DOE”) anticipates the technical potential of DER like rooftop solar, batteries, electric vehicles, and flexible industrial and building loads like smart water heaters and heat pumps could drive the evolution of energy grids and help industries around the world find manageable solutions to the energy access and climate change concerns (https://ibn.fm/4M2QV). Correlate Infrastructure Partners (OTCQB: CIPI) is a distributed energy solutions provider helping businesses in the commercial real estate industry adopt localized DER and find any necessary financial aids to fulfill their environmental, social and governance (“ESG”) strategies. Correlate Infrastructures recently reported a contract for one of the largest behind-the-meter solar installations in the United States, a 3.8 megawatts project at the Pennsylvania headquarters of global stored energy solutions leader EnerSys (https://ibn.fm/94S3m). The expertise of CIPI’s leadership team is providing the foundation for the company’s success, and CIPI turned a spotlight this month on its chief financial officer, Channing Chen, who first launched into the clean energy sector when he joined Solar Power Partners (now part of NRG Energy) nearly two decades ago. “With years of experience leading institutional financing initiatives at SPP, SunEdison and NRG Energy, I felt well-suited to leverage my finance and deal expertise with a more strategic focus (at Correlate Infrastructure Partners)”, Chen stated in the Dec. 5 interview (https://ibn.fm/LLCjg). “Specifically, I oversee all aspects of accounting and finance, investor relations, SEC reporting, and project finance, along with capital raising and negotiating corporate development transactions.” Chen stated a core element of his job is to make sure the right people are in place to help the company do things more efficiently and more cost effectively than its competitors. With $370 billion from the federal government dedicated to decarbonization efforts through the Inflation Reduction Act passed earlier this year, the DER solutions industry has “the biggest tailwind … ever” for its aims, he said. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter
• The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023
• CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023
• Through its research, CNS looks to tap into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019

On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the company’s progress, highlighting the successful expansion of its pivotal Berubicin trial into Europe within the quarter. He further noted how the move was integral to the company achieving interim analysis by mid-2023 which, he believes, will be a transformational milestone (https://ibn.fm/HtX2Y). CNS has, since its inception, shown its commitment to solving the unmet need associated with the treatment of GBM. This condition affects approximately 13,000 people in the United States each year. It is estimated that up to 50% of original malignant tumors of the central nervous system (“CNS”) are glioblastomas, with diagnosed patients having an average time of about a year after diagnosis and only 10% or less surviving to five years (https://ibn.fm/MXDZt). Despite this prevalence, treatment options for GBM are scarce, and CNS hopes to address this with its lead drug candidate, Berubicin. Regarded as an innovative first-in-its-class anthracycline to appear to cross over the blood-brain barrier and kill tumor cells as a potential treatment option for GBM, Berubicin has shown great promise in the clinical trials conducted thus far. For example, at least 44% of patients in a recent clinical trial showed a clinical response, with one demonstrating a lack of detectable cancer cells following the study (https://ibn.fm/d8TMM). As it works toward interim analysis of clinical trials in mid-2023, CNS looks to build on the successful patient enrollment and dosing in France, which, so far, brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe. The company also looks to build momentum to advance its program across the finish line. “This expansion into Europe drives us toward our goal of interim analysis, expected in mid-2023, which we believe has the potential to be (a) transformational milestone. Moving forward, we are focused on building momentum and advancing this important program across the finish line,” noted Mr. Climaco (https://ibn.fm/55kqY). Mr. Climaco emphasizes that CNS’s focus and priorities are firmly anchored in advancing its clinical development for Berubicin to bring meaningful treatment to GBM patients. He further notes that this focus is driven by a significant unmet need, particularly given that recurrent GBM does not have an “approved therapy anywhere in the world.” Through this research, CNS inches closer to tapping into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019. In addition, it looks to offer a potentially viable solution to GBM, a condition that currently affects as many as 5 out of every 100,000 individuals (https://ibn.fm/4uAJg). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Nearly all automotive OEMs have plans to include lidar sensors within their assisted and automated driving platforms
• Gaining public trust in the ability of vehicles to operate safely while providing automated driving features will be a key milestone for widespread adoption
• L2+/L3 ADAS is likely to be an enabler as it helps ease the public with broader hands-free functions while maintaining the ability to take over as needed
• Cepton’s lidar sensors are uniquely positioned to benefit from these core industry growth trends and the Company remains committed to delivering superior driving experiences with added safety and convenience

Automotive OEMs have made headlines recently for accelerating their commitment to hands-free driving. Ford announced during its third quarter earnings release this year that they intend to focus on developing L2/L3 ADAS capabilities and Honda also announced plans to include hands-free features as standard in all their cars by 2030. Given these developments, drivers, and the broader public need to develop trust in next generation automotive technology starting with the assurance that their safety won’t get compromised. Companies like Cepton (NASDAQ: CPTN), an innovator within the lidar industry aiming to enhance road safety through the development of next generation ADAS technology, could become key in winning the race to wider public acceptance of driverless cars. The Company remains committed to safe and autonomous transportation for everyone as it works toward delivering lidar solutions that are reliable, efficient, and versatile. The statistics paint a rather grim picture of American road safety. In 2020, around 2.3 million people were injured in traffic accidents, while 38,824 people were killed on U.S. roads (https://ibn.fm/uljlh). Human errors are a leading cause of these accidents. However, despite its potential to turn this grave reality around, the promise of autonomous vehicles – to make driving safer by reducing and/or eliminating human errors – still has work to accomplish to gain widespread public acceptance. Recent research shows that many people still don’t feel safe in fully self-driving cars. More specifically, only 27% of the global population believes they would be safe in them (https://ibn.fm/XeO53). Car manufacturers may believe that drivers are ready for a self-driving future, but some drivers are concerned self-driving technology isn’t ready or mature enough. For example, an AAA survey published earlier this year reported that an astonishing 77% of responders want car manufacturers to focus on improving currently available ADAS systems in new vehicles (https://ibn.fm/I6cGI). This is an area in which Cepton can shine since their initial focus has been around creating products to enable higher levels of ADAS at a price point that promotes mass market adoption. Since fully self-driving technology and related roadway infrastructure / regulations need time to be developed and approved, ADAS remains a top priority for automakers. ADAS aspires to automate and enhance the driver experience and provide a safer journey by helping with monitoring, alerting, braking, and steering. It is designed to handle elements of the driving experience, aiming to reduce driver error by stepping in if the driver makes a mistake, and helps make driving much more convenient. But to be able to help drivers navigate and respond to potential hazards on the road, ADAS technology must win their trust – and for this, it needs to be accurate and work in a consistent way. False alarms, lack of clarity over what triggers alerts, or the system’s failure to react can all hinder drivers’ confidence in this essential technology. Cepton believes that improving the ADAS experience for today’s drivers by giving them a stronger sense of safety is essential to preparing our society for a future where a fully assisted vehicle is everywhere. The Company’s high-performing lidar technology can be seamlessly integrated into the vehicle and strives to achieve the highest levels of accident prevention. Designed to create a precise 3D map of a vehicle’s surrounding environment, Cepton’s technology can enable cars to perceive hazards and make decisions with greater certainty (https://ibn.fm/VVUtg). Cepton continues to make strides in terms of building driver confidence and next-generation sensor technology. For example, Cepton recently announced that it is collaborating with NVIDIA to add Cepton lidar models into NVIDIA DRIVE Sim™, in which the company aims to advance the development of lidar-based assisted and autonomous driving functionalities for all customers in various classifications (https://ibn.fm/JwMFn). Cepton works to enable safer roads today and in the future. ADAS could be the key differentiating feature among automotive brands that compete in the crowded automotive space and car makers that place safety before autonomy could be the ones that win the race toward a self-driving future. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Cost-cutting becomes a priority for businesses looking to remain strong during record inflation
• “It’s always a question of what to prioritize and which costs to minimize while preserving the quality of your product,” states a Forbes article
• Cerberus ensures that companies not only stay more secure but also build a culture of cybersecurity

In a fragile economy with a possible recession looming on the horizon, savvy companies are taking a close look at ways to tighten their belts. As they do so, a recent Forbes article cautions wise business leaders to keep cybersecurity in the forefront (https://ibn.fm/ui99g), a strategy that Cerberus Cyber Sentinel (NASDAQ: CISO) can help with. The article details “why cyber protection should become a ‘must-have,’ not a ‘nice-to-have’ in your business decision-making process and why you should prioritize it in times of economic uncertainty.” Titled “Why Businesses Shouldn’t Cut Cybersecurity Costs—Especially During a Crisis,” the piece notes that “the global economy has been shaken enough times in the past two years for some experts to say the world will likely enter another recession soon.” “While it’s essential to work on a renewed crisis management plan, it’s always a question of what to prioritize and which costs to minimize while preserving the quality of your product,” the article continues. “In evaluating risks, it might seem reasonable at first to eliminate the costs that don’t directly affect production. If your business has never been exposed to a real cyber threat before, expenses for security systems might seem too pricey — a common misconception.” The article calls out three key reasons why cybersecurity shouldn’t be on the budget chopping block: cutting cybersecurity costs may result in greater expenditures in the long run; neglecting cybersecurity compliance can have a legal — and financial — impact on a business; and an up-to-date security architecture can be a competitive advantage. This is where insight from seasoned partners can help organizations identify new efficiencies, business enablement, and ROI that can be tied to their cybersecurity investments. Still, the savings in prevention alone make security improvements worthwhile. “Neglecting simple details such as installing cyber protection and providing cybersecurity awareness to your employees can cost you more in the long run,” reported Forbes. “According to the most recent IBM report, the current cost of a data breach for a company averages $4.35 million—and this price only grows yearly.” Additionally, Forbes explained that “fulfilling certain cybersecurity compliance requirements is not only a question of mediating potential financial risks for your business — in many cases, it’s simply a law. As a business, you are free to protect your own physical and intellectual property in a way that benefits you. However, when it comes to things you don’t own (the customer or partner data that you work with or market information that you gather), you have to fulfill your local data management and protection requirements.” Finally, the article observed that cybersecurity literacy is growing in business-to-business and business-to-consumer sectors, with many existing and potential customers and partners beginning to realize how serious the implications of a careless attitude to cyber risks might be. “If you cannot ensure that the data they provide is secure, why should they choose your service over a competitor that fulfills their requirements?” the article asks. Cerberus Sentinel understands these points, recognizing that cyber resilience is a journey that is often made unnecessarily complex and confusing in today’s marketplace. “Cerberus Sentinel is on a mission to demystify and accelerate our clients’ journey to cyber resilience, empowering organizations to securely grow, operate, and innovate,” the company states on its website. Widely recognized as a managed cybersecurity and compliance provider, Cerberus is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilizes the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information, visit the company’s website at www.CerberusSentinel.com. NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Hillcrest Energy Technologies recently unveiled a commercial prototype of its 800-volt, 250-kilowatt Zero Voltage Switching (“ZVS”) traction inverter
• The production of a commercial prototype comes only months after the company had published white papers, extolling the potential of their revolutionary technology
• The inverter will be developed and integrated alongside Hillcrest’s partners, Hercules Electric Mobility as well as a separate Tier 1 automotive supplier
• The company envisions its inverter technology being deployed with batteries, electric motors, generators, fuel cells and any other power source requiring power conversion

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology company focused on developing transformative power conversion technologies, has recently announced the completion of its 800-volt, 250-kilowatt Zero Voltage Switching (“ZVS”) traction inverter commercial prototype. Whilst initially directed towards the electric vehicle industry, Hillcrests ZVS inverter technology can eventually be applied with batteries, electric motors, generators, fuel cells or virtually any other power source where power conversion is needed. A key issue affecting both electric vehicle manufacturers as well as owners is efficiency losses emanating from a vehicle’s powertrain. A vital component in an EV powertrain, an inverter seeks to convert DC charge from the battery to AC to drive the electric. The more efficient the inverter is, the more efficient the vehicle is as a whole and the greater the amount of driving range that can be extracted from the battery. Having published white papers on its revolutionary technology mere months ago (https://ibn.fm/7xkWx), the production of a commercial prototype in such a short span of time has goes a long way towards validating Hillcrest’s technological claims. “We’ve validated our core technology and will continue working with Hercules Electric Mobility and a Tier 1 automotive supplier, our previously announced co-development partners, on integrating our ZVS traction inverter into their specific powertrain applications,” commented Hillcrest CTO Ari Berger. “Implementing our technology in these systems, expected to occur by Q2 2023, will mark another important milestone by transitioning the technology out of our lab and into real world demonstrations of the Hillcrest ZVS inverter in commercial applications.” Hillcrest’s ZVS, or soft switching capabilities will seek to overcome challenges habitually found in hard-switched wide-bandgap devices such as silicon carbide (“SiC”) traction inverters. Through the material elimination of switching losses, Hillcrest’s inverter technology has been shown to reduce the thermal management needed across the entire powertrain system. This in turn can result in substantial savings in the manufacturing process, reducing system complexity and improving system reliability by reducing stress placed upon power devices. “In just one year, Hillcrest progressed from a 10-kilowatt proof of concept to a 250-kilowatt ZVS traction inverter commercial prototype,” said CEO Don Currie. “Add the incredible customer interest we’ve already received, highlighted by two announced MOUs, and I believe we are clearly demonstrating our ability to be at the forefront and deliver innovations that will advance power electronics for the next generation of mobility. Leveraging upon their next generation inverter solution, Hillcrest Energy Technologies will seek to deliver a step-change in the performance of electric vehicles. Not only does the inverter deliver motor efficiency gains such that it has the potential to reduce the overall size of an EV’s battery, but the reduction in battery size and consequently, the battery’s cost, can drive savings for both automotive manufacturers and end consumers. Berger remarked, “[The] high efficient of an inverter is only the beginning of the story…from there we have several benefits at the system level.” For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• 66% of US consumers (80% of consumers aged 18-34) are willing to pay more for products made with sustainability in mind
• The luxury home décor market is expected to reach $207 billion by 2027, growing from $118 billion in 2020 at a CAGR of 5.14%
• Coyuchi guarantees the highest environmental and ethical standards through its certifications – The Global Organic Textile Standard (“GOTS”), Fair Trade Certified, and MADE SAFE(R)
• Coyuchi is built upon four foundational pillars – protecting the environment, innovating circular design, living sustainably, and enriching the community – with over 1400 SKUs made from 100% organic cotton
• The company is currently accepting investment through Regulation A+ offerings

Coyuchi is setting the gold standard in sustainable luxury home goods, offering sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. For 30 years, Coyuchi has explored organic farming and sustainable textiles, and guarantees the highest environmental and ethical standards through its acquisition of certifications, including The Global Organic Textile Standard (“GOTS”), Fair Trade Certified, and MADE SAFE(R). Backed by a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base driving the fast-growing organic luxury market, Coyuchi is positioned to propel its new growth phase as the world awakens to sustainability at scale.

The home décor market consists of anything that makes a home look more stylish and aesthetically pleasing while having a specific purpose for the occupants within the home. Products that fall within this category include carpets, rugs, shelves, towels, paintings, bedding, and more, with interior designers charging fees that range from $2,000 to $10,000, depending on the size of the home. In 2020, the United States was the single largest national market for luxury home décor, next to Europe, which dominated the global market, driven by strong demand in the UK, France, Germany, and Italy. The demand for luxury home décor is expected to grow at a CAGR of 5.14% from 2021 to 2027, from $118 billion in 2020 to $207 billion in 2027 (https://ibn.fm/lKvkr).

Despite the threat of rising inflation, which has grown from 1.4% in 2020 to 8.5% in 2022, 66% of consumers (80% of young consumers ages 18-34) report a willingness to pay more for sustainable products (https://ibn.fm/TI0dx). To be considered sustainable, products must provide environmental, social, and economic benefits while protecting public health and the environment over the entire lifecycle of the product – from the extraction of raw materials to manufacturing, distribution, and disposal.

Coyuchi is built upon four foundational pillars – protecting the environment, innovating circular design, living sustainably, and enriching the community. Coyuchi’s product assortment consists of consciously designed products spread across 1400 SKUs. The company’s current product base consists of four core categories:

• Bedding – Coyuchi provides a full suite of sustainable, organic, high-quality sheets, duvet covers, blankets, and throws
• Bath – luxury line of towels, bath rugs, and mats
• Apparel – premium apparel for men and women, including robes, sweaters, pants, and pajamas
• Lifestyle – the lifestyle category offers over 135 SKUs ranging from organic napkins to crossbody totes

The global market for organic bedding had an estimated value of $814.3 million in 2020 and is expected to grow at a CAGR of 4.9%, resulting in a value of $1.1 billion by 2027 (https://ibn.fm/Y83Dm). Coyuchi’s organic bedding uses only 100% organic cotton materials, a standard utilized across all its products. In 2021, the company earned $33.3 million in net sales, amounting to 26% YoY growth, approximately five times the industry average of only 5%. The company also achieved customer growth resulting in 200,000 active customers and averaging 35% repeat customer purchase rates.

Coyuchi is currently accepting investment as part of a Regulation A+ offering. The company’s profile can be found on Manhattan Street Capital or through its Offering Circular.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs
• In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements
• Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)
• The company has also started investigating DehydraTECH-CBD as a potential therapeutic for the treatment of dementia and diabetes and is planning to begin another study on DehydraTECH-nicotine pouch performance
• Over the course of the year, Lexaria was granted four new patents, and entered into separate licensing agreements with four new partners

In his concluding remarks in this year’s letter to shareholders published January, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka underlined that “Management of [the company] feels we are on track, on schedule, and on budget to deliver what we hope and expect will be great results in 2022” (https://ibn.fm/cD2BJ). Since then, the company has achieved crucial milestones that can well be described as “great results,” and rightly so. These milestones are centered around Lexaria’s patented DehydraTECH(TM) drug delivery technology.

DehydraTECH can be applied to many drugs and fat-soluble active pharmaceutical ingredients (“APIs”), with the resultant formulation boasting better speed of onset, bioavailability, and brain absorption. So far, Lexaria has evidenced, through pharmacokinetic (“PK”) studies, that its technology delivers higher quantities of cannabidiol (“CBD”), oral nicotine, and antiviral drugs into the bloodstream in less time, properties that are technically known as increased bioavailability.

For Lexaria, however, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought the company closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (“IP”) portfolio has received additional patent protection in different jurisdictions around the world. Lexaria has also entered into multiple manufacturing and/or licensing agreements with global partners.

Research Programs

DehydraTECH-Processed PDE5 Inhibitor

Lexaria kicked the year off with an announcement of ground-breaking findings in an animal study evaluating DehydraTECH-processed sildenafil, a phosphodiesterase (“PDE5”) inhibitor used in the management of erectile dysfunction. The study, whose results were announced February 2, showed that the DehydraTECH formulation delivered more sildenafil (roughly 70% more drug) and at a faster rate (about 25% faster) than the concentration-matched, generic control formulation (https://ibn.fm/fSxz3).

DehydraTECH-Processed CBD

In 2022, much like in 2021, Lexaria’s biggest area of investigation was CBD – or, more specifically, DehydraTECH-processed CBD. The company expanded the scope of its research to include not only investigations on hypertension or high blood pressure, a condition on which it had completed two human studies (HYPER-H21-1 and HYPER-H21-2) the year prior, but also diabetes, seizures, and dementia.

Building on the HYPER-H21-1 study, a 24-person study that evidenced a rapid and sustained drop in blood pressure, and HYPER-H21-2, which showed that DehydraTECH-CBD caused a 23% average reduction in overnight blood pressure and reduced arterial stiffness, Lexaria also released the findings of its 16-person HYPER-H21-3 study in April this year. This third study evidenced that the pulmonary artery systolic pressure was attenuated by about 5 mmHg or 41% overall in male participants (https://ibn.fm/6DBAM).

The positive findings from the HYPER-H21-3 study set the stage for the commencement of the fourth human clinical study (“HCS”), HYPER-H21-4, the most comprehensive study Lexaria has ever undertaken, that same month (https://ibn.fm/7179M). A 66-person randomized, double-blinded, placebo-controlled, cross-over study, HYPER-H21-4 was designed as a multi-week study whose dosing was completed in July with no serious adverse events reported. That was a vital outcome given that the main objective of most FDA-registered Phase I studies is to prove safety and tolerability.

This news was a precursor to even more positive news reported in late October when Lexaria announced that HYPER-H21-4 “may be the world’s first study to evidence a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral CBD therapy, using Lexaria’s patented DehydraTECH-CBD capsule formulation.”

The study showed a significant BP reduction by 2.5 weeks, with this attenuation sustained over the entire five weeks of dosing. Moreover, Lexaria also observed that the decreases in BP were similar in persons receiving treatment with standard-of-care BP medication as in persons who were not undergoing any current treatment, suggesting DehydraTECH-CBD’s potential abilities to offer additive BP reduction benefits above and beyond the therapeutic improvements of standard BP medication. This can have important regulatory implications.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” Chris Bunka commented. “DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study. Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD.”

HYPER-H21-4 was designed to enhance Lexaria’s probability of success with its expected Investigational New Drug (“IND”) application to seek the US Food and Drug Administration (“FDA”) approval to begin registered clinical testing. Against the backdrop of the findings from this study, and having already received positive feedback from a pre-IND meeting with the FDA, according to an August press release (https://ibn.fm/OQl3x), Lexaria is on track to file the full IND application in 2023. (Following the pre-IND meeting, the FDA confirmed its support for an abbreviated approval pathway in line with section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.)

Meanwhile, in a separate three-part animal study that kicked off in March that aimed to assess the effectiveness of DehydraTECH-CBD in reducing seizure activity compared to the FDA-approved seizure medication Epidiolex (https://ibn.fm/X6zl1), Lexaria evidenced that DehydraTECH-CBD can be more efficacious at lower doses than Epidiolex. Additionally, the company observed that DehydraTECH-CBD can act more rapidly than Epidiolex. According to Lexaria, work is ongoing to complete the third and final part of the study that intends to establish the dose required to achieve seizure inhibition in 50% of the animals tested or ED50 (https://ibn.fm/hOsRb).

In addition to the hypertension and seizure studies, Lexaria recently commenced separate investigations on the potential therapeutic use of DehydraTECH-CBD in both diabetes and dementia. Dubbed DIAB-A22-1, the study investigating  DehydraTECH-CBD’s potential utility in the treatment of diabetes kicked off on November 8 (https://ibn.fm/V45Lm), while DEM-A22-1, the study on the potential use of DehydraTECH-CBD in dementia, begun a couple of days later on November 10 (https://ibn.fm/xp2mS).

DehydraTECH-Processed Nicotine

Calendar 2022 also marked the year when Lexaria began expanding its research on nicotine to include human subjects. Having resolved the manufacturing and logistics challenges that had previously pushed back the commencement time as well as having received Independent Review Board (“IRB”) approval for the planned human oral nicotine study, NIC-H22-1, Lexaria expects to begin dosing in December 2022 (https://ibn.fm/6L0fJ).

A 36-person human PK, randomized, double-blinded, cross-over-study carried out in current cigarette smokers, NIC-H22-1 will see each participant receiving only one brand of oral nicotine pouch on each of the three visits to the laboratory over a period of weeks. Upon administration, each person will undergo both subjective and objective evaluations, with vital signs such as respiratory rate, heart rate, blood pressure, and temperature also collected. Overall, the study is specifically designed to compare the performance of Lexaria’s DehydraTECH-nicotine pouch to On!’s (a pouch brand manufactured by Altria) and Zyn’s (the world’s leading nicotine pouch product manufactured by Swedish Match).

Competition in the nicotine pouch category is heating up, with PMI have just completed its US$16 billion acquisition of Swedish Match.

Previously, Lexaria had demonstrated in animal study NIC-A21-1 that oral nicotine pouches processed using DehydraTECH were 10 to 20 times faster in reaching peak delivery of nicotine to the bloodstream than controls.

Patents

In 2022, Lexaria continued to strengthen its intellectual property portfolio, receiving four new patents as described below:

• In March, Australia granted Lexaria a patent entitled “Compositions Infused with Nicotine Compounds and Methods to Use Thereof” that covers most oral forms of nicotine, including sprays, gums, pouches, capsules, lozenges, tablets, and pills. The patent also covers various forms of nicotine, including free base nicotine, polymer resins of nicotine, nicotine salts, and other forms of nicotine complexes (https://ibn.fm/o9j34).
• In April, the United States Patents and Trademark Office (“USPTO”) granted Lexaria its first-ever patent for using DehydraTECH technology to enhance the delivery of antiviral drugs (https://ibn.fm/GVR4X).
• In July, Lexaria received its fourth patent granted in Japan, entitled “Lipophilic Active Agent Infused Compositions with Reduced Food Effect,” which acknowledges the ability of DehydraTECH to deliver APIs more effectively regardless of the presence of foods within the gastrointestinal system (https://ibn.fm/B7VuC).
• In August Lexaria received a new patent in Mexico that covers multiple claims, including but not limited to the treatment of hypertension, neurological diseases, diabetes, hepatic diseases, and more (https://ibn.fm/7RM1Q).

With the receipt of the four patents in 2022, Lexaria now has 27 worldwide patents granted, with about 50 more patents pending worldwide. The company believes that should the remaining patent applications become granted patents, its ability to generate meaningful license revenue from its IP may increase from multiple other countries and regions outside of the United States. And if this year’s licensing agreements are anything to go by, Lexaria is progressively inching closer to this goal, one partner at a time.

Licensing Agreements

Generally, the company’s granted patents help to buttress a part of the company’s business plan, which according to its latest annual report, is to “encourage new and existing participants to license and utilize DehydraTECH to enable enhanced performance of their products” (https://ibn.fm/FzUTU). To that end, this calendar year saw the company onboard new partners who have licensed the DehydraTECH technology for use in their respective markets. Anchored in licensing agreements announced in June, the licenses include:

• A European and United Kingdom DehydraTECH license for medical cannabis applications from wholly owned subsidiary Lexaria Pharmaceutical Corp. to Valcon Medical A/S, a European contract manufacturing organization (“CMO”) that manufactures medical cannabis extracts for the European Union (“EU”) and the UK (https://ibn.fm/ciTUJ)
• An exclusive commercial licensing agreement granted to Premier Wellness Science Co. Ltd. for the Japanese non-pharmaceutical market for the use of DehydraTECH with CBD and hemp ingredients in oral liquid and non-liquid products, topical, hair, lip-care, and cosmetics products (https://ibn.fm/0f8D0)
• A five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals of Ireland, a CMO, for the manufacturing and distribution of DehydraTECH-processed cannabinoid API powders within Europe, Australia, and New Zealand (https://ibn.fm/FjMBZ)
• Two agreements – a manufacturing operating agreement and a commercial license agreement – with Atlanta-based BevNology LLC. (https://ibn.fm/vEY4J)

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SideChannel is a company making cybersecurity accessible and simple, especially for small and mid-sized businesses (“SMBs”)
• The company provides cybersecurity services in the form of virtual CISOs (“vCISOs”), engineering services that enable the vCISOs to provide operational day-to-day security and privacy to clients, and proprietary security software called Enclave
• SideChannel’s differentiator from its competition is its team of experts, and recently the company hired IT and cybersecurity veteran Sean Higgins as Principal Consultant
• In this role, Sean will help client companies’ CISOs and senior management evaluate and have greater levels of confidence in their security programs

SideChannel (OTCQB: SDCH), a company focused on making cybersecurity more accessible and simple, especially for small and mid-sized businesses (“SMBs”), recently expanded its team with the hiring of Sean Higgins as Principal Consultant (https://ibn.fm/AeZGL).

An information technology (“IT”) veteran with over 35 years of experience, almost 30 of which have been focused on cybersecurity, Sean previously worked as the Chief Technology Officer (“CTO”) and Co-Founder at Herjavec Group, a global cybersecurity product and services provider. In his Principal Consultant role at SideChannel, Sean will help SideChannel’s clients’ in-house Chief Information Security Officers (“CISOs”) and management assess and have confidence in their security programs.

Higgins’ onboarding is timely, given the prevailing cybersecurity challenges SMBs face and the ever-growing volume of threats. According to a July 2022 article in Forbes, SMBs face more hurdles than larger corporations when trying to safeguard their computing and networking infrastructure against the growing number of cyberattacks and allied threats. The drawbacks, the article notes, include a lack of resources, skills, and staff (https://ibn.fm/EeciE). And as the 2022 CISO Survey of Small Cyber Security Teams report, which was quoted in the article, established, this problem is further compounded by the fact that small security teams are often allocated small budgets. It comes as no surprise then that these teams are paying attention to fewer security alerts in 2022 than they did the previous year.

The study further documented the problems SMBs face when operating threat protection products. The biggest include having overlapping capabilities of different technologies, viewing the full picture of an attack, and deploying and maintaining disparate technologies on one machine. Moreover, the report ranked the lack of skilled security personnel as the top barrier to maintaining security posture. Other barriers include excessive manual data analysis, a remote workforce, ineffective user awareness training, and a lack of budget.

With the U.S. Cybersecurity and Infrastructure Security Agency (“CISA”) warning of imminent cyberattacks in the wake of Russia’s invasion of Ukraine (https://ibn.fm/uMIXf), SideChannel is positioning itself as the cybersecurity company whose products and services are designed to help SMBs get around the existing challenges. SDCH specifically provides cybersecurity services in the form of virtual CISOs (“vCISOs”), engineering services that enable the vCISOs to provide day-to-day operational security and privacy to clients, and proprietary security software called Enclave. Enclave allows organizations to micro-segment their corporate networks, thus preventing network-wide access by hackers in the event of an attack.

In a presentation delivered during the Windy City Roundup 2022 Conference held in October, SideChannel CTO and Co-Founder Nick Hnatiw explained why the company offers vCISO services. (A recording of the webcast is available upon registration at https://ibn.fm/TCOY1. CISOs, Nick began, implement and create strategy documents that guide the security of organizations. These documents detail how to protect the company from cyber threats and ensure compliance with regulations.

“SideChannel has discovered that all organizations need to have a CISO, but they all cannot afford one,” Nick underlined the gap in the market. To further emphasize this point, a fall 2021 study, entitled The State of Cybersecurity Leadership and Readiness, found that 45% of companies do not employ a CISO. In addition, 60% of the companies delegate the role of developing their cybersecurity strategies was to IT and compliance teams or even the executive leadership rather than to dedicated CISOs (https://ibn.fm/M8EPb).

With the aforementioned 2022 study having already cited budget constraints as one of the hurdles to implementing cybersecurity programs or hiring personnel with the requisite skills, SideChannel is filling an existing gap. The idea behind providing vCISO services, Nick noted, “is to fractionalize the time of the CISO and distribute it to many organizations.” SideChannel matches companies with an expert vCISO so the organization can assess cyber risk and ensure cybersecurity compliance.

“Our differentiator to our competition is our people. SideChannel is the leading cybersecurity firm with a growing list of former enterprise-level CISOs to deliver vCISO services to clients,” SideChannel’s website reads.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications
• The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more
• The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025

A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid can reduce hospitalization and death among high-risk COVID-19 patients, there are situations where it is not recommended due to ritonavir’s ability to increase concentrations of drugs that strongly depend on hepatic cytochrome P-450 3A metabolism. The study further supports the argument and necessity for radically improved COVID-19 treatments (https://ibn.fm/h26qS). BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products primarily treating infectious and autoimmune diseases, announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy (https://ibn.fm/j25pD). BiondVax is developing a pipeline of alpaca-derived NanoAb therapies to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. Compared with current monoclonal antibodies (“mAbs”) treatments, BiondVax’s NanoAbs exhibit strong potential for superior patient convenience, safety, and clinical outcomes, at a lower cost. BiondVax’s study was designed using an industry-standard animal model for COVID-19 therapeutics and vaccines and compared weight loss in two groups of hamsters after infection with SARS-COV-2. The experimental group was treated with the company’s anti-COVID-19 NanoAb, administered via inhalation, starting one day after infection. The control group was treated in the same manner but with saline as a placebo. These studies were conducted by The Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”), Germany, two world-renowned institutions. The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast, on average the weight of the experimental group using BiondVax’s NanoAb therapy declined only 3.80%. The successful result of the study was further supported by eight other tracked parameters, including heart rate and social behaviors, indicating that the group treated with NanoAbs experienced a milder, shorter illness. According to Research and Markets, the global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025. A key factor driving the therapy market’s growth is the fact that social restrictions in place during the pandemic have generally eased, and preventative vaccine and booster uptake is waning, with an expected consequence of more COVID infections requiring treatment. (https://ibn.fm/lx8iz). “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness,” said BiondVax’s Chief Science Officer (“CSO”), Dr. Tamar Ben-Yedidia Ph.D. “Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive) treatment. Results of the trial will inform design of the first-in-human clinical trial of the inhaled NanoAb COVID-19 therapy, which is planned for late 2023.” For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV